ALCIDION GROUP LIMITED (ALC)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ALC - ALCIDION GROUP LIMITED

FNArena Sector : Healthcare services
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -1.4
Index:

Alcidion Group provides clinical information technology to support clinicians in decision making, ensuring quality of care for patients. The company operates in Australia and the UK. It listed on the ASX in 2011.

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.047

18 Apr
2024

0.003

OPEN

$0.04

6.82%

HIGH

$0.05

2,729,213

LOW

$0.04

TARGET
$0.05 6.4% upside
OTHER COMPANIES IN THE SAME SECTOR
ACL . AHX . BMT . CAJ . DOC . EBO . HLS . M7T . MDR . MPL . MVF . NHF . PSQ . RHC . SHL .
FNARENA'S MARKET CONSENSUS FORECASTS
ALC: 1
Title FY22
Actual		 FY23
Actual		 FY24
Forecast		 FY25
Forecast
EPS (cps) xxx N/A - 0.6 xxx
DPS (cps) xxx N/A 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 201820192020202120222023
EPS Basic xxxxxxxxxxxxxxx-0.3
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx40.4 M
Book Value Per Share xxxxxxxxxxxxxxx7.1
Net Operating Cash Flow xxxxxxxxxxxxxxx0.2 M
Net Profit Margin xxxxxxxxxxxxxxx-8.95 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 201820192020202120222023
Return on Capital Employed xxxxxxxxxxxxxxx-3.93 %
Return on Invested Capital xxxxxxxxxxxxxxx-3.86 %
Return on Assets xxxxxxxxxxxxxxx-2.90 %
Return on Equity xxxxxxxxxxxxxxx-3.93 %
Return on Total Capital xxxxxxxxxxxxxxx-5.01 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-0.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 201820192020202120222023
Short-Term Debt xxxxxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxxxxx1 M
Total Debt xxxxxxxxxxxxxxx2 M
Goodwill - Gross xxxxxxxxxxxxxxx68 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx15 M
Price To Book Value xxxxxxxxxxxxxxx1.34

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 201820192020202120222023
Capex xxxxxxxxxxxxxxx0.5 M
Capex % of Sales xxxxxxxxxxxxxxx1.12 %
Cost of Goods Sold xxxxxxxxxxxxxxx39 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx6 M
Research & Development xxxxxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxxxxx-

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

0.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

19/04/2024

3

Hold

$0.05

6.38%

Alcidion Group's March Q update was largely in line with Bell Potter's expectations. The modest revenue growth in the first 9 months
was largely due to an under-resourced NHS delaying UK tender timelines, causing persistent delays in awarding competitive contracts to vendors.

The broker expects Alcidion will achieve its guidance of positive cash flow in the second half, driven by increased cash receipts in Q4, historically the best performing quarter. The cash balance is $6.5m as of end-March with no debt.

Recent cost-cutting has been prudent in response to delayed revenue expectations, Bell Potter suggests, and the broker remains cautious on the timing for UK tenders considering the multiple delays that have persisted over the last 12-18 months.

Hold and 5c target retained.

FORECAST
Bell Potter forecasts a full year FY24 dividend of 0.00 cents and EPS of minus -0.60 cents.
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -0.20 cents.
Access Stockbroker Research History >

ALC STOCK CHART

FNArena News on ALC

1
Australian Broker Call *Extra* Edition – Mar 20, 2024

Mar 20 2024 - Daily Market Reports
2
Australian Broker Call *Extra* Edition – Mar 12, 2024

Mar 12 2024 - Daily Market Reports
3
FNArena Corporate Results Monitor – 05-03-2024

Mar 05 2024 - Australia
4
Australian Broker Call *Extra* Edition – Feb 09, 2024

Feb 09 2024 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Nov 15, 2023

Nov 15 2023 - Daily Market Reports

Latest Healthcare services News

1
Capitol Health’s Higher Margin Outlook

Mar 13 2024 - Small Caps
2
Treasure Chest: Ramsay Health Care

Oct 26 2023 - Treasure Chest
3
Timing Seems Right For Alcidion Group

Jun 21 2023 - Small Caps
4
No Enthusiasm To Combine ACL & Healius

Mar 21 2023 - Australia
5
Dr Boreham’s Crucible: Alcidion

Dec 13 2022 - Small Caps
6
No Straight Covid-Relief For Ramsay Health Care

Nov 15 2022 - Australia
7
Dr Boreham’s Crucible: Mach7 Technologies

Nov 14 2022 - Small Caps
8
Negative Industry Trends Impact Australian Clinical Labs

Aug 12 2022 - Small Caps
9
Healius Offers Digital Carrot, Base Remains Soft

May 25 2022 - Australia
10
Ramsay Stakes Future on Mental Health

Dec 20 2021 - Australia